Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: A prospective national study in the Netherlands

British Journal of Haematology

Volumn 157, Issue 6, 2012, Pages 747-752

  Eckhardt, Corien L ^a   Mauser Bunschoten, Evelien P ^b   Peters, Marjolein ^a   Leebeek, Frank W G ^c   van der Meer, Felix J M ^d   Fijnvandraat, Karin ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Factor VIII concentrates; Inhibitor; Mild moderate haemophilia a; Prospective study; Surgery

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GENOTYPE; HEMOPHILIA A; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; SPINAL CORD HEMORRHAGE; SURGICAL APPROACH; TREATMENT DURATION;

ADULT; BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PROSPECTIVE STUDIES;

EID: 84861531092     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09119.x     Document Type: Article

References (25)

1. Astermark, J., Berntorp, E., White, G.C. & Kroner, B.L. (2001) The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia, 7, 267-272.
2. Astermark, J., Altisent, C., Batorova, A., Diniz, M.J., Gringeri, A., Holme, P.A., Karafoulidou, A., Lopez-Fernandez, M.F., Reipert, B.M., Rocino, A., Schiavoni, M., von, D.M., Windyga, J. & Fijnvandraat, K. (2010) Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia, 16, 747-766.
3. Bril, W.S., MacLean, P.E., Kaijen, P.H., van den Brink, E.N., Lardy, N.M., Fijnvandraat, K., Peters, M. & Voorberg, J. (2004) HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation. Haemophilia, 10, 509-514.
4. van den Brink, E.N., Timmermans, S.M., Turenhout, E.A., Bank, C.M., Fijnvandraat, K., Voorberg, J. & Peters, M. (1999) Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593->Cys substitution. Thrombosis and Haemostasis, 81, 723-726.
5. Colvin, B.T., Hay, C.R., Hill, F.G. & Preston, F.E. (1995) The incidence of factor VIII inhibitors in the United Kingdom, 1990-93. Inhibitor Working Party. United Kingdom Haemophilia Centre Directors Organization. British Journal of Haematology, 89, 908-910.
6. Coppola, A., Di Minno, M.N. & Santagostino, E. (2010) Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. British Journal of Haematology, 150, 515-528.
7. Eckhardt, C.L., Menke, L.A., Van Ommen, C.H., Van Der Lee, J.H., Geskus, R.B., Kamphuisen, P.W., Peters, M. & Fijnvandraat, K. (2009) Intensive peri-operative use of factor VIII and the Arg593 -> Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. Journal of Thrombosis and Haemostasis, 7, 930-937.
8. Fijnvandraat, K., Turenhout, E.A., van den Brink, E.N., ten Cate, J.W., van Mourik, J.A., Peters, M. & Voorberg, J. (1997) The missense mutation Arg593 -> Cys is related to antibody formation in a patient with mild hemophilia A. Blood, 89, 4371-4377.
9. Gouw, S.C. & van den Berg, H.M. (2009) The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Seminars in thrombosis and Hemostasis, 35, 723-734.
10. Hay, C.R., Ludlam, C.A., Colvin, B.T., Hill, F.G., Preston, F.E., Wasseem, N., Bagnall, R., Peake, I.R., Berntorp, E., Mauser Bunschoten, E.P., Fijnvandraat, K., Kasper, C.K., White, G. & Santagostino, E. (1998) Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.[see comment]. Thrombosis and Haemostasis, 79, 762-766.
11. Hay, C.R., Palmer, B., Chalmers, E., Liesner, R., Maclean, R., Rangarajan, S., Williams, M. & Collins, P.W. (2011) Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood, 117, 6367-6370.
12. Jacquemin, M., Vantomme, V., Buhot, C., Lavend'homme, R., Burny, W., Demotte, N., Chaux, P., Peerlinck, K., Vermylen, J., Maillere, B., van der, B.P. & Saint-Remy, J.M. (2003) CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood, 101, 1351-1358.
13. Kempton, C.L., Soucie, J.M., Miller, C.H., Hooper, C., Escobar, M.A., Cohen, A.J., Key, N.S., Thompson, A.R. & Abshire, T.C. (2010) In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. Journal of Thrombosis and Haemostasis, 8, 2224-2231.
14. Leebeek, F.W., Kappers-Klunne, M.C. & Jie, K.S. (2004) Effective and safe use of recombinant factor VIIa (NovoSeven) in elderly mild haemophilia A patients with high-titre antibodies against factor VIII. Haemophilia, 10, 250-253.
15. Mannucci, P.M. (2000) Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia, 6(Suppl 1), 60-67.
16. Matzinger, P. (2002) The danger model: a renewed sense of self. Science, 296, 301-305.
17. Mauser- Bunschoten, E.P., Fransen De Putte Van, D.E. & Schutgens, R.E. (2009) Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia, 15, 853-863.
18. Oldenburg, J., El-Maarri, O. & Schwaab, R. (2002) Inhibitor development in correlation to factor VIII genotypes. [Review] [37 refs]. Haemophilia, 8(Suppl 2), 23-29.
19. Peerlinck, K. & Jacquemin, M. (2010) Mild haemophilia: A disease with many faces and many unexpected pitfalls. Haemophilia, 16, 100-106.
20. Plug, I., van der Bom, J.G., Peters, M., Mauser-Bunschoten, E.P., van de Goede-Bolder, A., Heijnen, L., Smit, C., Zwart-van Rijkom, J.E., Willemse, J. & Rosendaal, F.R. (2004) Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood, 104, 3494-3500.
21. Sharathkumar, A., Lillicrap, D., Blanchette, V.S., Kern, M., Leggo, J., Stain, A.M., Brooker, L. & Carcao, M.D. (2003) Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. Journal of thrombosis and haemostasis, 1, 1228-1236.
22. Thompson, A.R., Murphy, M.E., Liu, M., Saenko, E.L., Healey, J.F., Lollar, P. & Scandella, D. (1997) Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation. Blood, 90, 1902-1910.
23. Verbruggen, B., Novakova, I., Wessels, H., Boezeman, J., van den Berg, M. & Mauser-Bunschoten, E. (1995) The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thrombosis and Haemostasis, 73, 247-251.
24. Von Auer, ch., Oldenburg, J., Von Depka, M., Escuriola-Ettinghausen, C., Kurnik, K., Lenk, H. & Scharrer, I. (2005) Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Annals of NewYork Academy Sciecne, 1051, 498-505.
25. Wight, J. & Paisley, S. (2003) The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia, 9, 418-435.